fda bpc 157 category 2 compounding 2023 FDA's own advisory committee voted 8-6 Thursday. BPC-157, on the list now, for ulcerative colitis. staff argued against it, laid out the data gaps, the whole case. Panel overruled them In 2023, the FDA deemed

Conservative approach (better tolerated) Slower escalation: Week 1-6: 0.6mg weekly Week 7-12: 1.2mg weekly Week 13-18: 1.8mg weekly Week 19+: 2.4mg weekly (or stay at 1.8mg) Benefits: Fewer side effects Better tolerability Good for GI-sensitive people Still effective (slightly less weight loss) Maintenance at lower dose: Some maintain at 1.8mg or 2.0mg 8-10% weight loss still achievable Better long-term sustainability More affordable Aggressive protocol (maximum weight loss) Higher doses (some trials): Week 1-4: 0.6mg weekly Week 5-8: 1.2mg weekly Week 9-12: 2.4mg weekly (faster) Week 13-16: 3.0mg weekly Week 17+: 4.5mg weekly (maximum) Warning: Higher side effect risk Nausea very common at 4.5mg Not necessary for most people Only if excellent tolerability Research setting primarily Expected additional benefit: 4.5mg: ~11-12% vs 2.4mg: ~10% Modest additional loss May not justify side effects Individualized decision Combination with semaglutide dosing CagriSema protocol: Start both simultaneously OR add cagrilintide to existing semaglutide Semaglutide: Titrate to 2.4mg over 16-20 weeks Cagrilintide: Titrate to 2.4mg over 12-16 weeks Both weekly injections (can be same day) Sequential approach (if already on semaglutide): Stable on semaglutide 2.4mg for 4+ weeks Add cagrilintide starting 0.6mg weekly Titrate cagrilintide to 2.4mg over 12 weeks Continue both Expected results: 15-25% body weight loss Superior to either alone Well-documented synergy See our cagrilintide and semaglutide , semaglutide dosage calculator , and tirzepatide dosing guide guides

First, verify your technique

Access our compounded GHK-Cu here: References Pickart, L., & Margolina, A

Youll also see red flags that call for testing